ATE530183T1 - Substituierte indole und ihre verwendung als integrin-antagonisten - Google Patents

Substituierte indole und ihre verwendung als integrin-antagonisten

Info

Publication number
ATE530183T1
ATE530183T1 AT02709193T AT02709193T ATE530183T1 AT E530183 T1 ATE530183 T1 AT E530183T1 AT 02709193 T AT02709193 T AT 02709193T AT 02709193 T AT02709193 T AT 02709193T AT E530183 T1 ATE530183 T1 AT E530183T1
Authority
AT
Austria
Prior art keywords
sup
sub
alpha
beta
integrins
Prior art date
Application number
AT02709193T
Other languages
English (en)
Inventor
Tianbao Lu
Louis Lafrance
Thomas Markotan
Juan Jose Marugan
Victor Marder
Prichard David U
Beth Anaclerio
Zihong Guo
Wenxi Pan
Kristi Leonard
Bruce E Tomczuk
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE530183T1 publication Critical patent/ATE530183T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02709193T 2001-01-29 2002-01-29 Substituierte indole und ihre verwendung als integrin-antagonisten ATE530183T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26426001P 2001-01-29 2001-01-29
US32451901P 2001-09-26 2001-09-26
PCT/US2002/002366 WO2002060438A1 (en) 2001-01-29 2002-01-29 Substituted indoles and their use as integrin antagonists

Publications (1)

Publication Number Publication Date
ATE530183T1 true ATE530183T1 (de) 2011-11-15

Family

ID=26950369

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02709193T ATE530183T1 (de) 2001-01-29 2002-01-29 Substituierte indole und ihre verwendung als integrin-antagonisten

Country Status (11)

Country Link
US (4) US6855722B2 (de)
EP (1) EP1425010B8 (de)
JP (1) JP4615826B2 (de)
KR (1) KR100854424B1 (de)
AT (1) ATE530183T1 (de)
AU (1) AU2002243692B2 (de)
CA (1) CA2436130A1 (de)
ES (1) ES2376161T3 (de)
MX (1) MXPA03006772A (de)
NZ (1) NZ539682A (de)
WO (1) WO2002060438A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092130A2 (en) * 2003-04-07 2004-10-28 Kalypsys, Inc. N-containing heteroaromatic compounds as modulators of ppars and methods of treating metabolic disorders
EP1620088A4 (de) * 2003-04-28 2007-08-29 Bayer Pharmaceuticals Corp Indolessigsäure-derivate und ihre verwendung als pharmazeutische mittel
EP1689389A4 (de) 2003-12-04 2009-06-17 Nat Health Research Institutes Indol-verbindungen
JP2007534702A (ja) * 2004-04-26 2007-11-29 バンダービルト・ユニバーシティ 胃腸毒性の低い治療薬としてのインドール酢酸、及びインデン酢酸誘導体
WO2006034418A2 (en) 2004-09-21 2006-03-30 Athersys, Inc. Benzimidazole acetic acids exhibiting crth2 receptor antagonism and uses thereof
JP2008513512A (ja) 2004-09-21 2008-05-01 アサーシス， インク． Ｃｒｔｈ２受容体拮抗作用を示すインドール酢酸およびこれらの使用
WO2006108040A1 (en) * 2005-04-05 2006-10-12 Janssen Pharmaceutica, N.V. Substituted indoles and their use as integrin antagonists
WO2007010723A1 (ja) * 2005-07-20 2007-01-25 National University Corporation Kanazawa University トリプトファン誘導体及びその用途
US7977359B2 (en) * 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) * 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
WO2007149456A2 (en) 2006-06-19 2007-12-27 Vanderbilt University Methods and compositions for diagnostic and therapeutic targeting of cox-2
US8667716B2 (en) * 2007-01-31 2014-03-11 Tony L Torrance Adjustable sole support system
US7770309B2 (en) * 2007-01-31 2010-08-10 Dashamerica, Inc. Adjustable arch insole
ES2618812T3 (es) * 2011-01-20 2017-06-22 Merck Sharp & Dohme Corp. Antagonistas del receptor mineralocorticoide
US9346803B2 (en) 2011-10-17 2016-05-24 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
EP3050878B1 (de) 2013-09-24 2021-10-27 FUJIFILM Corporation Neuartige stickstoffhaltige verbindung oder salz davon oder metallkomplex davon
CN107428755B (zh) 2015-03-25 2020-03-03 富士胶片株式会社 含氮化合物或其盐的制造方法以及它们的制造中间体
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
EA201991123A1 (ru) 2016-11-08 2019-11-29 ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV
ES2898835T3 (es) 2016-11-08 2022-03-09 Bristol Myers Squibb Co Azol amidas y aminas como inhibidores de la integrina alfav
MA46743A (fr) 2016-11-08 2019-09-18 Bristol Myers Squibb Co Acides propioniques à substitution en position 3 en tant qu'inhibiteurs d'intégrine alpha v
AU2017359030A1 (en) 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Pyrrole amides as alpha v integrin inhibitors
ES2984394T3 (es) 2016-11-08 2024-10-29 Bristol Myers Squibb Co Compuestos mono y espirocíclicos que contienen ciclobutano y azetidina como inhibidores de la integrina alfa v
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
SG11201907820SA (en) 2017-02-28 2019-09-27 Morphic Therapeutic Inc Inhibitors of (alpha-v)(beta-6) integrin
US11292802B2 (en) * 2017-11-07 2022-04-05 Bristol-Myers Squibb Company Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors
UY38352A (es) 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibidores de integrina alfavbeta6
CA3109534A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiting .alpha.v .beta.6 integrin
EP3843727A4 (de) 2018-08-29 2022-08-17 Morphic Therapeutic, Inc. Inhibitoren von (alpha-v)(beta-6)-integrin
CN114426543A (zh) * 2020-10-29 2022-05-03 中国科学院大连化学物理研究所 一种铑催化合成三取代吡咯化合物的方法
EP4374698B1 (de) 2022-11-28 2025-08-20 The Procter & Gamble Company Pyridiniumester

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234942A (en) 1984-10-19 1993-08-10 Ici Americas Inc. Heterocyclic amides and leucotriene antagonistic use thereof
DE4027278A1 (de) 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
JPH0764841B2 (ja) 1990-10-03 1995-07-12 ファイザー製薬株式会社 インドール誘導体およびその用途
GB9309324D0 (en) 1993-05-06 1993-06-16 Bayer Ag Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
CA2190870A1 (en) 1994-05-27 1995-12-07 George D. Hartman Compounds for inhibiting osteoclast-mediated bone resorption
MX9801228A (es) 1995-08-14 1998-05-31 Scripps Research Inst METODOS Y COMPOSICIONES UTILES PARA LA INHIBICION DE ANGIOGENESIS MEDIADA POR ALFAV beta5.
DE19548709A1 (de) 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
CA2195697A1 (en) 1996-02-02 1997-08-03 Masahumi Kitano Novel substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof
PT891325E (pt) 1996-03-29 2002-07-31 Searle & Co Derivados do acido fenilpropanoico para-substituido como antagonistas de integrina
KR20000016301A (ko) 1996-05-31 2000-03-25 빙검 더글라스 에이. 혈관 형성 억제에 유용한 방법 및 조성물
CA2259224A1 (en) 1996-06-28 1998-01-08 Merck Patent Gesellschaft Mit Beschraenkter Haftung Phenylalamine derivatives as integrin inhibitors
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
UA60311C2 (uk) 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
EP0946164A4 (de) * 1996-10-30 2000-08-23 Merck & Co Inc Integrin antagonisten
EP0949259B1 (de) 1996-12-26 2001-06-20 Nikken Chemicals Company, Limited N-hydroxyharnstoffderivate und sie enthaltende medizinische zubereitungen
ATE299023T1 (de) 1997-12-17 2005-07-15 Merck & Co Inc Integrinrezeptor antagonisten
US6066648A (en) 1997-12-17 2000-05-23 Merck & Co., Inc. Integrin receptor antagonists
KR20010033473A (ko) 1997-12-23 2001-04-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ａｃｅ 저해제-ｍｍｐ 저해제의 병용 제제
SK12742000A3 (sk) 1998-02-25 2001-05-10 Genetics Institute, Inc. Inhibítory fosfolipázových enzýmov, farmaceutický prostriedok s ich obsahom a ich použitie
GB9814801D0 (en) 1998-07-09 1998-09-09 Univ Strathclyde Integrin dependent cell adhesion inhibitors
UA71586C2 (en) 1998-12-04 2004-12-15 Smithkline Beecham Corp A vitronectin receptor antagonist
UA74781C2 (en) * 1999-04-02 2006-02-15 Abbott Lab Antiinflammatory and immumosuppressive compounds inhibiting cell adhesion
DE10006139A1 (de) 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
AU2001288485A1 (en) * 2000-08-29 2002-03-13 Balekudru Devadas Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists

Also Published As

Publication number Publication date
ES2376161T3 (es) 2012-03-09
US7241789B2 (en) 2007-07-10
EP1425010A1 (de) 2004-06-09
EP1425010A4 (de) 2009-07-29
US20050209225A1 (en) 2005-09-22
KR100854424B1 (ko) 2008-08-27
NZ539682A (en) 2006-03-31
JP2004533993A (ja) 2004-11-11
JP4615826B2 (ja) 2011-01-19
MXPA03006772A (es) 2004-10-15
US6855722B2 (en) 2005-02-15
US20020169200A1 (en) 2002-11-14
WO2002060438A1 (en) 2002-08-08
KR20030088024A (ko) 2003-11-15
US20070219233A1 (en) 2007-09-20
AU2002243692B2 (en) 2006-06-08
EP1425010B1 (de) 2011-10-26
US20050250771A1 (en) 2005-11-10
EP1425010B8 (de) 2012-03-28
CA2436130A1 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
EP1425010A4 (de) Substituierte indole und ihre verwendung als integrin-antagonisten
DE60038686D1 (de) Oheptan-derivate und ihre verwendung als integrin-rezeptor-antagonisten
DZ3263A1 (fr) Antagonistes du recepteur de l'alpha v integrine
DE69720771T2 (de) Integrin antagonist
NO20012975D0 (no) Nye bifenyl og bifenylanaloge forbindelser som integrinantagonister
IL177291A0 (en) Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
DE69713582D1 (de) Zimtsäurederivate und deren verwendung als integrin-antagonisten
ATE496893T1 (de) Isochinolinonderivate und deren verwendung als medikamente
EP0901373A4 (de) Alpha v Beta 3 ANTAGONISTEN
ATE413388T1 (de) Muskarin antagonisten
DE69431069D1 (de) Cyclische amidderivate als neurokinin a antagonisten
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
EP1315501A4 (de) Alpha v integrin-rezeptor-antagonisten
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
DE60327375D1 (de) Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten
DE60326263D1 (de) Pyrimidin-sulfonamide und ihre verwendung als endothelin-rezeptor-antagonisten
ATE348827T1 (de) Substituierte benzofurane und benzothiophene, verfahren zu deren herstellung und verfahren zu deren anwendung als integrinantagonisten
ATE365155T1 (de) 1,3-disubstituierte azetidinderivate zur verwendung als antagonisten des ccr-3-rezeptors bei der behandlung von entzündlichen und allergischen krankheiten
DE60311000D1 (de) Indolderivate und deren verwendung als 5-ht liganden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties